NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Income Taxes
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Income Taxes of $60.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxes · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for the quarter ending 2026-06-30 was -$59.60M, a 15000.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for the quarter ending 2026-03-31 was $119.80M, a 677.92% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for the quarter ending 2025-12-31 was $35.50M, a 35.57% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for the quarter ending 2025-09-30 was -$70.10M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for fiscal 2025 was -$18.80M, a 137.38% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for fiscal 2024 was $50.30M, a 45.09% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in income taxes for fiscal 2023 was $91.60M.
| Period end | Increase (Decrease) in Income Taxes 3 month | Increase (Decrease) in Income Taxes 6 month | Increase (Decrease) in Income Taxes 9 month | Increase (Decrease) in Income Taxes 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$59.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $60.20M 10-Q · filed 2026-07-31 | $95.70M derived: sum of 3 quarters · filed 2026-07-31 | $25.60M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $119.80M 10-Q · filed 2026-05-05 | $155.30M derived: sum of 2 quarters · filed 2026-05-05 | $85.20M derived: sum of 3 quarters · filed 2026-05-05 | $85.60M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $35.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$34.60M derived: sum of 2 quarters · filed 2026-02-11 | -$34.20M derived: sum of 3 quarters · filed 2026-07-31 | -$18.80M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$70.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$69.70M derived: sum of 2 quarters · filed 2026-07-31 | -$54.30M 10-Q · filed 2025-10-28 | $800.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $15.80M 10-Q · filed 2026-07-31 | $70.90M derived: sum of 3 quarters · filed 2026-07-31 | |
| 2025-03-31 | $15.40M 10-Q · filed 2026-05-05 | $70.50M derived: sum of 2 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $55.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $50.30M 10-K · filed 2026-02-11 | ||
| 2024-09-30 | -$4.80M 10-Q · filed 2025-10-28 | |||
| 2023-12-31 | $91.60M 10-K · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |